NEW YORK (GenomeWeb) – Oxford Cancer Biomarkers (OCB) announced today that it has licensed its suite of in vitro colorectal cancer diagnostics to Chinese precision medicine firm My-BioMed Biotechnology (MBM).
Under the terms of the deal, MBM will have access to OCB's ColoTox, ColoProg, and ColoPredict tests and technologies, which will be offered in China through a purpose-built biomedical laboratory. Additional terms were not disclosed.
ColoTox is designed to predict a patient's risk of life-threatening toxicity from fluoropyrimidine-based chemotherapy by analyzing germline DNA for the presence of risk alleles. ColoProg is performed after colorectal cancer surgery to stratify a patient's risk for relapse based on various genetic biomarkers, and ColoPredict identifies healthy individuals at increased risk for developing colorectal cancer by analyzing DNA collected from a mouth swab.
"We are looking forward to working closely with MBM to tailor our offerings to the specific needs of the Chinese market and building a robust product pipeline of diagnostics specifically aimed at the Chinese population," OCB Chief Medical Officer David Kerr said in a statement. "This is an important step in our mission to drive global access to technologies that allow patient stratification and individually tailored treatment pathways."